Opportunity Information: Apply for RFA DD 11 009
Apply for RFA DD 11 009
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Public Health Research for the Prevention of Complications of Bleeding Disorders" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.073 Birth Defects and Developmental Disabilities Prevention and Surveillance.
- This funding opportunity was created on Dec 9, 2010 and posted on Dec 9, 2010.
- Applicants must submit their applications by Mar 4, 2011 On time submission requires that electronic applications be error free and made available to CDC for processing from eRA Commons on or before the deadline date. Applications must be submitted to and validated successfully by Grants.gov/eRA Commons no later than 500 PM Eastern Time. NoteHHS/CDC grant submission procedures do not provide a period of time beyond the application due date to correct any error or warning notices of noncompliance with application instructions that are identified by Grants.gov or eRA systems (i.e., error correction window).. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- The number of recipients for this funding is limited to 6 candidate(s).
- Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The CDC funding opportunity RFA DD 11 009, titled "Public Health Research for the Prevention of Complications of Bleeding Disorders," was a discretionary grant program offered through a cooperative agreement mechanism to support independent public health research focused specifically on complications that arise in people with bleeding disorders. The central aim was to generate new, generalizable knowledge that could be applied beyond a single clinic or local setting, with emphasis on understanding how often complications occur (incidence), how widespread they are (prevalence), what factors increase risk, and what the broader burden and consequences look like for individuals and health systems. A key priority was research that could inform prevention strategies, meaning studies that do more than describe problems and instead point toward actionable approaches to reduce complications and improve outcomes.
The work supported under this opportunity was positioned in the public health domain rather than basic laboratory science. In practical terms, that means the CDC was looking for projects that could clarify real-world patterns of complications in populations with bleeding disorders, identify modifiable risk factors, and improve understanding of downstream impacts such as disability, quality of life effects, healthcare utilization, and long-term health consequences. Projects could address a range of complication types, provided the research was designed to produce broadly applicable findings and contribute to prevention. Because the funding instrument was a cooperative agreement, applicants would generally expect a more involved federal partnership than a standard grant, with CDC engagement that can include technical input, coordination, or collaboration consistent with cooperative agreement norms.
The program anticipated making up to six awards. Individual award amounts were expected to fall between an annual floor of $75,000 and a ceiling of $200,000. There was no cost sharing or matching requirement, which reduced barriers for organizations that might not be able to commit non-federal funds. The opportunity fell under CFDA 93.073, tied to birth defects and developmental disabilities prevention and surveillance, reflecting the CDC organizational and programmatic context for this announcement.
Eligibility was listed as unrestricted, meaning it was broadly open to many entity types, subject to any additional eligibility clarifications contained in the full announcement text. As a result, potential applicants could include universities, hospitals, nonprofits, state or local health entities, and other organizations capable of conducting rigorous public health research.
Key administrative details were also explicit. The opportunity was posted on December 9, 2010, with an application deadline of March 4, 2011. Applications had to be submitted electronically through Grants.gov and successfully validated through Grants.gov and eRA Commons by 5:00 PM Eastern Time on the due date. Importantly, the CDC noted there was no extra error-correction window beyond the deadline, so submissions needed to be error-free and fully accepted by the systems before the cutoff. The opportunity was later archived on April 3, 2011, indicating it is no longer open.
For applicants needing help accessing the full announcement, the CDC directed inquiries to the Procurement and Grants Office, Technical Information and Management Section, reachable by phone at 770-488-2700, with a general email contact listed but not specified in the provided text.
Frequently Asked Questions (FAQs)
What is the title and identifier of this CDC funding opportunity?
The opportunity is CDC RFA DD 11 009, titled "Public Health Research for the Prevention of Complications of Bleeding Disorders."
What type of funding mechanism was used?
This was a discretionary grant program offered through a cooperative agreement mechanism.
What was the main purpose of the program?
The central aim was to support independent public health research focused on complications that arise in people with bleeding disorders, with the goal of generating new, generalizable knowledge that can be applied beyond a single clinic or local setting.
What kinds of research questions did CDC emphasize?
The opportunity emphasized understanding how often complications occur (incidence), how widespread they are (prevalence), what factors increase risk, and what the broader burden and consequences look like for individuals and health systems.
Was the program focused on prevention, or only on describing complications?
A key priority was research that could inform prevention strategies. The CDC emphasized studies that go beyond describing problems and instead point toward actionable approaches to reduce complications and improve outcomes.
Was basic laboratory science eligible under this opportunity?
The work supported under this opportunity was positioned in the public health domain rather than basic laboratory science.
What does "public health domain" mean in the context of this announcement?
In practical terms, CDC was looking for projects that clarify real-world patterns of complications in populations with bleeding disorders, identify modifiable risk factors, and improve understanding of downstream impacts such as disability, quality of life effects, healthcare utilization, and long-term health consequences.
What types of complications could be studied?
Projects could address a range of complication types, as long as the research was designed to produce broadly applicable findings and contribute to prevention.
How many awards did CDC expect to make?
The program anticipated making up to six awards.
What was the expected award size?
Individual award amounts were expected to fall between an annual floor of $75,000 and a ceiling of $200,000.
Was cost sharing or matching required?
No. There was no cost sharing or matching requirement.
What CFDA number was associated with this opportunity?
The opportunity fell under CFDA 93.073, tied to birth defects and developmental disabilities prevention and surveillance.
Who was eligible to apply?
Eligibility was listed as unrestricted, meaning it was broadly open to many entity types, subject to any additional eligibility clarifications contained in the full announcement text.
What types of organizations could potentially apply under "unrestricted" eligibility?
Potential applicants could include universities, hospitals, nonprofits, state or local health entities, and other organizations capable of conducting rigorous public health research.
When was the opportunity posted?
The opportunity was posted on December 9, 2010.
What was the application deadline?
The application deadline was March 4, 2011.
How did applicants have to submit their applications?
Applications had to be submitted electronically through Grants.gov.
Were there any additional submission system requirements besides submitting through Grants.gov?
Yes. Applications also had to be successfully validated through both Grants.gov and eRA Commons by 5:00 PM Eastern Time on the due date.
What was the exact submission cutoff time?
Applications needed to be validated by 5:00 PM Eastern Time on the due date.
Was there an error-correction window after the deadline?
No. The CDC noted there was no extra error-correction window beyond the deadline, so submissions needed to be error-free and fully accepted by the systems before the cutoff.
Is this funding opportunity still open?
No. The opportunity was archived on April 3, 2011, indicating it is no longer open.
What level of CDC involvement should applicants expect under a cooperative agreement?
Because the funding instrument was a cooperative agreement, applicants would generally expect a more involved federal partnership than a standard grant, with CDC engagement that can include technical input, coordination, or collaboration consistent with cooperative agreement norms.
Who could be contacted to request help accessing the full announcement?
CDC directed inquiries to the Procurement and Grants Office, Technical Information and Management Section.
What phone number was provided for assistance?
The phone number provided was 770-488-2700.
Was an email address provided for inquiries?
A general email contact was mentioned as being listed, but it was not specified in the information provided.
Browse more opportunities from the same category: Health
Next opportunity: Mitochondria in Cancer Epidemiology, Detection, Diagnosis and Prognosis (R01)
Previous opportunity: Epidemiologic Research and Surveillance in Epilepsy (U01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DD 11 009
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DD 11 009) also looked into and applied for these:
| Funding Opportunity |
|---|
| The Association of Genetic Biomarkers and Hereditary Hemochromatosis (U01) Apply for RFA DD 11 008 Funding Number: RFA DD 11 008 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $150,000 |
| Ruth L. Kirschstein National Research Service Awards for Individual Postdoctoral Fellowships in Muscular Dystrophy Research (F32) Apply for PA 11 075 Funding Number: PA 11 075 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Informatics Tools for High Throughput Sequence Data Analysis (SBIR) (R43/R44) Apply for RFA HG 10 019 Funding Number: RFA HG 10 019 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| Informatics Tools for High Throughput Sequence Data Analysis (U01) Apply for RFA HG 10 018 Funding Number: RFA HG 10 018 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Research Activities In Support Of Malaria Prevention and Control in the Republic Of Uganda As Part of the President s Malaria Initiative Apply for RFA GH 11 004 Funding Number: RFA GH 11 004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
| Pilot for State specific Cross Sectional Surveillance of Persons with Rare Disorders and Longitudinal Assessment of Outcomes Apply for RFA DD 11 004 Funding Number: RFA DD 11 004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Mendelian Disorders Genome Centers (U54) Apply for RFA HG 10 016 Funding Number: RFA HG 10 016 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Genome Sequencing and Analysis Centers (U54) Apply for RFA HG 10 015 Funding Number: RFA HG 10 015 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Muscular Dystrophy Surveillance Tracking and Research Network MD STARnet Feasibility of Expansion to other Muscular Dystrophies Apply for RFA DD 11 006 Funding Number: RFA DD 11 006 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $450,000 |
| Limited Competition for the Renewal of the National Cell Repository for Alzheimers Disease (NCRAD) (U24) Apply for PAR 11 080 Funding Number: PAR 11 080 Agency: National Institutes of Health Category: Health Funding Amount: $675,000 |
| Expanding Maternal and Neonatal Survival (EMAS) Apply for RFA 497 11 000002 Funding Number: RFA 497 11 000002 Agency: Indonesia USAID Jakarta Category: Health Funding Amount: $55,000,000 |
| HIV Prevention with Youth and Adults Program in Lesotho Apply for 674 11 0004 Funding Number: 674 11 0004 Agency: South Africa USAID Pretoria Category: Health Funding Amount: $17,000,000 |
| Clinical Sequencing Exploratory Research (U01) Apply for RFA HG 10 017 Funding Number: RFA HG 10 017 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Development of a Preliminary Evidence Base to Inform Decision making about Returning Research Results to Participants in Genomic Studies (R01) Apply for RFA HG 11 003 Funding Number: RFA HG 11 003 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Ethical, Legal, and Social Implications of Returning Research Results to Genomic Research Participants (R21) Apply for RFA HG 11 004 Funding Number: RFA HG 11 004 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Long Term MCH Training LEND Apply for HRSA 11 036 Funding Number: HRSA 11 036 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Disparities in Perinatal Health Border, Alaska and Hawaii Apply for HRSA 11 018 Funding Number: HRSA 11 018 Agency: Health Resources and Services Administration Category: Health Funding Amount: $750,000 |
| Improving Access to Hearing Health Care (STTR) R41/R42 Apply for RFA DC 12 002 Funding Number: RFA DC 12 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Improving Access to Hearing Health Care (SBIR) R43/R44 Apply for RFA DC 12 001 Funding Number: RFA DC 12 001 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| Ability of Individual and Integrated Tick Management (ITM) Technologies to Reduce the Entomological Risk of Lyme Disease Apply for RFA CK 11 005 Funding Number: RFA CK 11 005 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DD 11 009", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.